FibroSIGHT™ Plus: Precision in Fibrosis Assessment with AI-based Analysis

EASL 2026

27-30 May 2026 | Barcelona

HistoIndex at the EASL Congress

27-30 May 2026

HistoIndex is returning to this year’s EASL Congress in Barcelona with 6 accepted abstracts for poster presentations:

POSTERS

AI-Derived Macrophage Density Reveals Hot and Cold Fibrosis Endotypes with Distinct Biomarker Profiles in Metabolic Dysfunction–Associated Steatohepatitis

Presenter: Zoltan Derdak

WED-087 | Wednesday, 27 May 2026

MASLD: Diagnostics and non-invasive assessment

Impact of PNPLA3 p.I148M variant on qFibrosis-based collagen morphology in MASLD: analysis from Milan biobank cohort

Presenter: Giulia Periti

FRI-340 | Friday, 29 May 2026 

Fibrosis / Stellate cell biology

REG26-774: Efruxifermin improved digital pathology and noninvasive fibrosis measures in participants with MASH and advanced fibrosis or compensated cirrhosis: analysis of the HARMONY and SYMMETRY phase 2b trials

Presenter:Prof. Dr. Jörn M. Schattenberg

FRI-191 | Friday, 29 May 2026

MASLD: Therapy 

REG26-2279: Quantitative digital pathology reveals distinct fibrosis zonal patterns among subtypes of steatotic liver disease

Presenter: Prof. Dr. Jeong Hwan Park

THU-174 | Thursday, 28 May 2026

MASLD: Clinical aspects except therapy

REG26-3625: Natural history and predictors of fibrosis progression in metabolic dysfunction-associated steatotic liver disease (MASLD) – Longitudinal cohort study with paired liver biopsies

Presenter: Dr. Fahim Ebrahimi

THU-126 | Thursday, 28 May 2026 

MASLD: Clinical aspects except therapy

REG26-2637: A spatial metabolic atlas of liver lipid metabolism and fibrosis in metabolic dysfunction-associated steatotic liver disease

Presenter: Mojgan Masoodi

TOP-081 | Wednesday, 27 May 2026

MASLD: Diagnostics and non-invasive assessment